Alexandra I. Soto-Beasley

Alexandra I. Soto-Beasley

Auto-generated profile, based on publicly available information

Alexandra I. Soto-Beasley

Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2024 in Science Advances
Verified
Journal Article
Open access
YJYunjung Jin
Yunjung Jin
FLFuyao Li
Fuyao Li
ZLZonghua Li
Zonghua Li
TITadafumi C. Ikezu
Tadafumi C. Ikezu
JOJustin O’lEary
Justin O’lEary
NZNa Zhao
Na Zhao
Aggregated α-synuclein (α-SYN) proteins, encoded by the SNCA gene, are hallmarks of Lewy body disease (LBD), affecting multiple brain regions. However, the specific mechanisms underlying α-SYN pathology in cortical neurons, crucial for LBD-associated dementia, remain unclear. Here, we recapitulated α-SYN pathologies in human induced pluripotent stem cells (iPSCs)–derived cortical organoids generated from patients with LBD with SNCA gene triplication. Single-cell RNA sequencing, combined with functional and molecular validation, identified synaptic and mitochondrial dysfunction in excitatory neurons exhibiting high expression of the SNCA gene, aligning with observations in the cortex of autopsy-confirmed LBD human brains. Furthermore, we screened 1280 Food and Drug Administration–approved drugs and identified four candidates (entacapone, tolcapone, phenazopyridine hydrochloride, and zalcitabine) that inhibited α-SYN seeding activity in real-time quaking-induced conversion assays with human brains, reduced α-SYN aggregation, and alleviated mitochondrial dysfunction in SNCA triplication organoids and excitatory neurons. Our findings establish human cortical LBD models and suggest potential therapeutic drugs targeting α-SYN aggregation for LBD.

2 May 2025 in Science Advances
Verified
Journal Article
Open access
NTNicole Tamvaka
Nicole Tamvaka
ASAlexandra I. Soto-Beasley
Alexandra I. Soto-Beasley
MGMarios Gavrielatos
Marios Gavrielatos
MHMichael G. Heckman
Michael G. Heckman
YRYingxue Ren
Yingxue Ren
OROwen A Ross
Owen A Ross
Pick’s disease (PiD) is a rare neurodegenerative disorder defined by dementia, frontotemporal lobe atrophy, and 3-repeat tau inclusions. To elucidate PiD pathobiology, we performed the first bulk transcriptomics study on PiD using short- and long-read sequencing on the parietal cortex of 28 PiD and 15 control samples. We identified several significantly differentially expressed genes, with CCL2 displaying the strongest association with 3-repeat tau pathology and increased burden in PiD compared to those in 4-repeat tau progressive supranuclear palsy (PSP) cases. Investigation of co-expressed genes and pathways suggested the involvement of mRNA processing, mitochondrial function, and immune processes in disease pathobiology. Long-read RNA sequencing on a subset of samples (eight PiD and four control) proposed novel, potentially disease-associated transcripts for AZGP1 , CD44 , HSD11B2 , and WIF1 , predicted to result in truncated proteins. In conclusion, we observed transcriptomic changes in the parietal cortex of patients with PiD that may inform into clinically relevant biomarkers and therapeutic strategies.

1 April 2021 in Neuroscience Letters
Verified
Journal Article
Closed access
AWAnna I. Wernick
Anna I. Wernick
RWRonald L. Walton
Ronald L. Walton
ASAlexandra I. Soto-Beasley
Alexandra I. Soto-Beasley
SKShunsuke Koga
Shunsuke Koga
YRYingxue Ren
Yingxue Ren
OROwen A Ross
Owen A Ross

31 January 2022 in Journal of Movement Disorders
Verified
Journal Article
Open access
PDF file
DODiana Angelika Olszewska
Diana Angelika Olszewska
AMAllan McCarthy
Allan McCarthy
ASAlexandra I. Soto-Beasley
Alexandra I. Soto-Beasley
RWRonald L. Walton
Ronald L. Walton
OROwen A Ross
Owen A Ross
TLTim Lynch
Tim Lynch

24 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SGSophie Glendinning
Sophie Glendinning
JAJosé M. Arbelo
José M. Arbelo
LDLola Díaz-Feliz
Lola Díaz-Feliz
RZRocío Malo de Molina Zamora
Rocío Malo de Molina Zamora
SGSara Gomes
Sara Gomes
OLOswaldo Lorenzo-Betancor
Oswaldo Lorenzo-Betancor
Background: The VPS35 p.D620N variant causes autosomal dominant Parkinson’s disease (PD) and has been shown to activate the LRRK2 kinase pathway, resulting in increased Rab substrate phosphorylation in peripheral immune cells and elevated urinary bis(monoacylglycero)phosphate (BMP) levels. Recently, a VPS35 variant of unknown significance (c.959C>T; p.A320V) was described in two late-onset sporadic PD patients. Methods: We ascertained a family from the Canary Islands in which six siblings were chronically exposed to high doses of pesticides. Three siblings developed levodopa-responsive, akinetic-rigid PD, while the other three remained unaffected. Whole-exome sequencing was performed in the three affected siblings. The frequency of the resulting candidate variant was assessed in 23,327 PD patients and 9,235 controls from four independent cohorts. Members of this pedigree and unrelated controls were assessed for LRRK2 kinase activity in monocytes and neutrophils and BMP levels in urine. Results: The three affected siblings were all heterozygous for p.A320V, whereas the three unaffected siblings did not carry the variant. In the combined PD case-control cohort, p.A320V was identified in six patients and one control. However, unlike p.D620N, heterozygous carrier status for p.A320V was not associated with increased LRRK2 kinase activity or elevated urine BMP levels. Conclusions: While VPS35 p.A320V co-segregated with PD in this family, it did not exhibit the characteristic LRRK2-associated biomarker signature observed in VPS35 p.D620N carriers. It is possible that p.A320V exerts a subtle effect on VPS35 function that was not captured by the assays performed and that chronic pesticide exposure contributed to disease penetrance in this pedigree.

1 October 2026 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
TFTobias M. Franz
Tobias M. Franz
MGMarios Gavrielatos
Marios Gavrielatos
YWYsabella Wijaya
Ysabella Wijaya
ABAlexandra I. Beasley
Alexandra I. Beasley
SKSarah Kim-Hellmuth
Sarah Kim-Hellmuth
CCCatalina Cerquera-Cleves
Catalina Cerquera-Cleves
Background and ObjectivesEarly-onset Parkinson disease (EOPD), defined as symptom onset before 50 years of age, accounts for approximately 10% of patients and is suggested to have a greater genetic...